FY2025 Earnings Estimate for GENFIT Issued By HC Wainwright

GENFIT S.A. Unsponsored ADR (NASDAQ:GNFT) – Analysts at HC Wainwright issued their FY2025 earnings estimates for shares of GENFIT in a research note issued to investors on Tuesday, August 19th. HC Wainwright analyst B. Folkes forecasts that the company will earn $0.01 per share for the year. HC Wainwright has a “Buy” rating and a $9.00 price target on the stock. The consensus estimate for GENFIT’s current full-year earnings is $0.95 per share. HC Wainwright also issued estimates for GENFIT’s FY2026 earnings at ($0.90) EPS, FY2027 earnings at ($0.24) EPS, FY2028 earnings at ($0.90) EPS and FY2029 earnings at ($0.64) EPS.

GENFIT Stock Down 1.6%

Shares of NASDAQ GNFT opened at $4.2490 on Thursday. The company has a quick ratio of 1.23, a current ratio of 1.23 and a debt-to-equity ratio of 0.08. GENFIT has a 1-year low of $2.55 and a 1-year high of $6.42. The company has a fifty day moving average price of $3.90 and a 200 day moving average price of $3.85.

Hedge Funds Weigh In On GENFIT

A hedge fund recently bought a new stake in GENFIT stock. Millennium Management LLC bought a new position in GENFIT S.A. Unsponsored ADR (NASDAQ:GNFT) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 166,375 shares of the company’s stock, valued at approximately $611,000. Millennium Management LLC owned 0.33% of GENFIT at the end of the most recent quarter. 2.24% of the stock is owned by institutional investors.

About GENFIT

Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.